For certain hospitals participating in the 340B Drug Pricing Program, not every potential drug discount is guaranteed by federal law. This is especially relevant when purchasing orphan drugs. Under Section 340B(e) of the Public Health Service Act, orphan drugs are excluded from mandatory 340B ceiling pricing for Critical Access Hospitals (CAHs), Sole Community Hospitals (SCHs), Rural Referral Centers (RRCs), and free-standing cancer hospitals. However, manufacturers may voluntarily offer discounts on these medications.

This is where discretionary pricing becomes important. Unlike mandatory 340B pricing, discretionary discounts are offered at the manufacturer's discretion. Availability varies by drug and manufacturer, so regular verification is essential.

Why Should Hospitals Monitor Discretionary Pricing?

A hospital may assume that an orphan drug is automatically excluded from every possible discount because it falls under the orphan drug exclusion. That assumption can result in missed savings. On the other hand, continuing to apply a previously available discount without checking its current status can create purchasing and compliance concerns.

Hospitals should consider several practices to avail discretionary pricing:

• Review orphan drug designations and applicable indications.

• Verify manufacturer discount availability for individual drugs.

• Reassess pricing changes regularly.

• Maintain accurate purchasing and split-billing records.

• Coordinate pharmacy and finance teams around current pricing information.

How 340B Orphan Drug Solutions Can Help

Managing these details requires specialized knowledge and consistent follow-through. 340B Orphan Drug Solutions helps qualifying hospitals identify potential orphan drug overpayments, assess recoverable amounts, monitor manufacturer pricing, and support pricing corrections and recovery.

Its services also include customized orphan drug lists, split-billing integration support, quarterly updates, and team training.

Rather than treating discretionary discounts as a one-time research task, hospitals can build a repeatable process for identifying and capturing eligible savings.

Visit 340B Orphan Drug Solutions to explore specialized orphan drug recovery and discretionary pricing support.